Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules
Executive Summary
Teva's generic Remeron (mirtazapine) will have only five months of marketing exclusivity from its approval date due to FDA's current interpretation of the trigger for first-to-file 180-day marketing exclusivity under the Waxman/Hatch Act, Teva reported in its Feb. 18 earnings teleconference
You may also be interested in...
180-Day Exclusivity Is An “Incentive,” Not A “Right,” FTC Says
The Federal Trade Commission is calling 180-day generic exclusivity an "incentive," not a "right," in a filing with FDA opposing a citizen petition submitted by Ivax
180-Day Exclusivity Is An “Incentive,” Not A “Right,” FTC Says
The Federal Trade Commission is calling 180-day generic exclusivity an "incentive," not a "right," in a filing with FDA opposing a citizen petition submitted by Ivax
Glucophage XR Generics Will Be Early Test Of Bristol/FTC Settlement
The expiration of marketing exclusivity forGlucophage XR will provide an early test of the impact of Bristol-Myers Squibb's settlement with the Federal Trade Commission over Bristol's aggressive patent defense tactics